COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS
Abstract
The aim of our study was to conduct a pharmacoeconomic and cost analysis of the therapeutic use of anti-HIV drugs.
Material and methods. The study was based on the documented medical histories of HIV-infected patients; it also incorporated the data from the state-sponsored auctions and contracts for drug purchase, as well as the information from the website poisklekarstv.ru with recommendations for Moscow pharmacies. Both statistical and analytical approaches were used.
Results. We found that all drugs needed for the treatment of patients with HIV infection are available in Russia. These drugs appear in the updated list of the treatment standards approved for domestic use in Russia.
Conclusion. The difference between the government-sponsored prices and the retail prices of these medications has an impact on the costs of ant-HIV therapy.
About the Authors
M. B. Kubaeva
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Assistant of the Department of General and Clinical Pharmacology, post-graduate student,
ul. Miklukho-Maklaya, 10/3, Moscow, 117198
Y. Sh. Guchshina
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
PhD, Associate Professor of the Department of General and Clinical Pharmacology,
ul. Miklukho-Maklaya, 10/3, Moscow, 117198
References
1. Pokrovsky V. V. HIV infection and AIDS: clinical recommendations / Federal Scientific and Methodological Center for AIDS Prevention and Control; Ch. Ed. V. V. Pokrovsky [VICh-infektsiya i SPID: klinicheskie rekomendatsii. Federal’nyi nauchno-metodicheskii tsentr po profilaktike i bor’be so SPIDom (in Russian)]. Moscow. 2010; 187 p.
2. De Cock K. M., Ekpini E., Gnaore E., Kadio A., Gayle H. D. The public health implications of AIDS research in Africa. JAMA. 1994; 272 (6): 481-486.
3. Dixon S., McDonald S., Roberts J. The impact of HIV and AIDS on Africa’s economic development. BMJ. 2002; 324 (7331): 232-234.
4. Rosen S., Vincent J. R., MacLeod W., Fox M., Thea D. M., Simon J. L. The cost of HIV/AIDS to businesses in southern Africa. AIDS. 2004; 18 (2): 317-324.
5. Umenai T., Narula M., Onuki D., Yamamoto T., Igari T. International HIV and AIDS prevention: Japan / United States collaboration. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 14 (Suppl 2): 58-67.
6. Hecht R., Alban A., Taylor K., Post S., Andersen N. B., Schwarz R. Putting it together: AIDS and the millennium development goals. PLoS Med. 2006; 3 (11): e455.
7. Pavlos R., Phillips E. J. Individualization of antiretroviral therapy. Pharmgenomics Pers Med. 2012; 5: 1-17.
8. Pokrovsky V. V. Protocols of dispensary observation and treatment of HIV-infected patients. Epidemiology and infectious diseases. Current issues. 2012; 6, app.
9. Recommendations for the clinical management and treatment of HIV-infected adults in Europe, edition of November 2009. Paris: European Clinical Society for AIDS, 2012.
For citation:
Kubaeva M.B., Guchshina Yu.S. COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(2):41-43. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.2.041-043
Views: 741
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 